MedTrace Logo

Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace

NCT03272685 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 799

Last updated 2024-08-20

Study results available
· View outcomes & findings →

Summary

This project will examine the impact of very low nicotine content (VLNC) cigarettes in a complex tobacco and nicotine product marketplace. We will compare the number of cigarettes smoked and cigarette-free days in an experimental marketplace that contains VLNC cigarettes versus normal nicotine content (NNC) cigarettes.

Conditions

  • Tobacco Smoking
  • Nicotine Dependence

Interventions

DRUG

Very Low Nicotine Content Cigarettes

0.4 mg nicotine/g tobacco; 9 mg tar

DRUG

Normal Nicotine Content Cigarettes

15.8 mg nicotine/g tobacco; 9 mg tar

Sponsors & Collaborators

Principal Investigators

  • Dorothy Hatsukami, PHD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2022-09-30
Completion
2023-01-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03272685 on ClinicalTrials.gov